Prezentace na téma Parkinsonova nemoc + Antiparkinsonika

More documents

Recommendations

Info

<strong>Antiparkinsonika</strong> dopaminergní anticholinergní Rozd lení len antiparkinsonik Mechanismus ú inku prekurzor dopaminu (DA) agonisté DA receptor uvol ování DA inhibitor MAO B centrální anticholinergika Léky levodopa (L-dopa), L-dopa+ inhibitor dopadekarboxylázy (karbidopa, benserazid) +/inhibitor KOMT (entacapon, tolcapon) apomorfin, bromokryptin, lisurid, pergolid, dihydroergokriptin, ropinirol, pramipexol amantadin selegelin trihexyfenidyl, benzatropin, biperiden, orfe<strong>na</strong>drin (tricyklická antidepresiva, H 1 -antihistaminika)
Drugs affecting the metabolism of levodopa Enzymes in bold COMT = catechol-O-methyltransferase MAO-B = monoamine oxidase B Drugs which alter metabolism in boxed red italics
Page 1 and 2: Nikolina Kutinová Canová Farmakol
Page 3 and 4: Parkinsonova nemoc za azení azen P
Page 5 and 6: Progresivní ztráta dopaminergníc
Page 7: Nap . pars compacta substancia nigr
Page 10 and 11: Farmakoterapie PN Antiparkinsonika
Page 14 and 15: is probably the single most effecti
Page 16 and 17: lehké p íznaky, p sobí mírné f

Prezentace na téma Parkinsonova nemoc + Antiparkinsonika

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?